Iradimed (IRMD) Projected to Post Quarterly Earnings on Thursday

Iradimed (NASDAQ:IRMD) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 13th. Analysts expect Iradimed to post earnings of $0.45 per share and revenue of $19.20 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Iradimed Trading Up 2.4 %

IRMD stock opened at $62.67 on Thursday. The firm’s 50-day moving average is $56.49 and its two-hundred day moving average is $51.55. The company has a market capitalization of $794.03 million, a price-to-earnings ratio of 42.92 and a beta of 0.82. Iradimed has a 52 week low of $40.18 and a 52 week high of $63.29.

Insider Buying and Selling

In other Iradimed news, CFO John Glenn sold 2,500 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the sale, the chief financial officer now directly owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. This represents a 36.32 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 37.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, StockNews.com cut Iradimed from a “strong-buy” rating to a “buy” rating in a report on Wednesday.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.